#Germany #Spatial Biology #Oberkochen #Revolune GmbH #immunofluorescence

The Launch of Revolune GmbH: Transforming Spatial Biology

On April 15, 2026, Revolune GmbH, a newly established life sciences company, officially announced its commitment to simplifying spatial biology through innovative solutions in multiplex immunofluorescence reagents. This initiative is designed to enhance our understanding of complex biological systems, which can significantly support translational research and biopharmaceutical development.

In recent years, the field of biomedical research has evolved, increasingly relying on spatially resolved biomarker analysis to unravel the intricacies of tissue biology and expedite the path to new therapies. However, existing multiplex tissue analysis workflows pose substantial challenges, including technical complexities and reproducibility issues. These drawbacks have hindered broader adoption among researchers.

Revolune aims to bridge this gap by providing a suite of reagents designed to streamline tissue analysis workflows, making them more reliable, efficient, and scalable. The company's approach is centered on creating intuitive tools that allow researchers to focus on biological questions rather than getting bogged down by workflow complexities. According to Florian Leiss, the CEO of Revolune, “Our mission is straightforward – to shed light on what matters.” He emphasizes that the development of robust, scalable, and practical technologies for lab environments is vital for the advancement of spatial biology.

The company’s initial focus on multiplex immunofluorescence reagents enables researchers to visualize multiple biomarkers within the intact architecture of tissue, thereby unlocking deeper spatial insights for both translational and pharmaceutical applications. This clarity in workflow reliability is critical, as it allows scientists to achieve reproducible multiplexing with the simplicity akin to immunohistochemistry (IHC) workflows.

Florian Leiss, prior to founding Revolune, led strategic initiatives at ZEISS, focusing on advancing spatial biology workflows in biopharmaceutical settings. His transformative efforts in biomarker analysis through imaging culminated in the creation of Revolune, an independent startup designed to tackle significant barriers in spatial biology workflows.

Joining Leiss in this venture, Michaeli Deli has been appointed as the Chief Financial Officer, where she will play a pivotal role in driving the strategic growth and operational development of Revolune as the company embarks on the next phase of its expansion.

The launch also marks the introduction of an Early Access Program, inviting selected research groups to engage with Revolune's multiplex immunofluorescence technologies and collaborate on the next generation of spatial biology workflows. This initiative is expected to foster innovative research partnerships and accelerate advancements in the field.

For further inquiries and detailed information regarding their offerings, potential collaborators can visit their official website at https://revolune.de. Revolune’s commitment to advancing science through optimized multiplex immunofluorescence solutions represents a significant step towards overcoming existing limitations within the domain of spatial biology, aiming to enhance the outcomes of multidisciplinary research efforts.

In summary, Revolune GmbH stands at the forefront of spatial biology, dedicated to empowering researchers with the tools needed to illuminate complex biological questions effectively. With a vision aimed at enhancing the quality and efficiency of biomedical research, their innovative approaches are set to redefine the landscape of biological analysis.